NICE Move On Cabometyx Gives BMS Longer To Make Opdivo Case In Second Line RCC
Executive Summary
A NICE knock-back for Ipsen's Cabometyx in renal cell carcinoma (RCC) means less pressure on BMS's embattled Opdivo, but not for long if Ipsen is willing to compromise on price, warn analysts.